Alivus Life Sciences Limited has scheduled a meeting of the Board of Directors for Thursday, July 30, 2026. The primary purpose of this meeting is to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2026 (Q1 FY27).
In accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's 'Code of Conduct for Prevention of Insider Trading', the trading window has been closed for all 'designated persons' of the Company. The closure period is from July 1, 2026 to August 1, 2026 (both days inclusive). This closure is specifically for the purpose of considering and approving the Unaudited Financial Results for the quarter ended June 30, 2026.
The disclosure was signed by Rudalf Joseph Corriea, Company Secretary & Compliance Officer, on July 23, 2026 at 14:12:18 IST. The communication was addressed to both BSE Limited and the National Stock Exchange of India Limited.
Company CIN: L74900PN2011PLC139963